Ensoma is focused on creating potentially curative medicines for genetic diseases, immune disorders, and cancer by engineering hematopoietic stem cells (HSCs) directly within the body. The company's platform utilizes proprietary base editing or high-efficiency gene integration systems, combined with high-capacity virus-like particles (VLPs), to deliver durable genetic medicines in a single administration. This delivery system relies on VLPs that are designed to bind preferentially to HSCs, allowing them to carry DNA to the cell's nucleus. With a significant cargo capacity of 35 kilobases, these VLPs can transport a variety of sophisticated genomic engineering tools to introduce changes ranging from single base edits to large multi-gene insertions. Supported by a passionate team and top-tier investors, Ensoma is based in Boston and is committed to a global vision for genetic medicines.